Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07011589 · ClinicalTrials.gov registry record · Phase 1
Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)
A Phase 1 study, sponsored by M. Peter Marinkovich.
- Not yet
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT07011589: Clinical Trial Phase 1 study, sponsored by M. Peter Marinkovich.
NCT07011589 is a Phase 1 study that has not yet begun recruiting, run by M. Peter Marinkovich. The registered enrollment target is 18 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07011589, a Phase 1 study, has not yet begun recruiting, sponsored by M. Peter Marinkovich.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The study objective is to see if IV Efgartigimod and Vyjuvek treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) and IV Efgartigimod treatment in Epidermolysis Bullosa Acquisita (EBA) improves wound healing and affects the levels of C7 antibody levels in serum. Fewer wounds, more rapidly healing wounds, and decreased C7 antibodies could improve quality of life.
Primary Outcome
The proportion of patients who exhibit reduction in serum C7 antibody levels at week 26 as compared to week 1.
Interventions
- BIOLOGICAL Efgartigimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2026-07 |
| Est. Completion | 2028-01 |
| Phase | Phase 1 |
What is known before NCT07011589 opens enrollment
NCT07011589 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 1 intervention - of which Efgartigimod is the first listed.
NCT07011589 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07011589 about?
NCT07011589 is a clinical study titled "Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)". The study objective is to see if IV Efgartigimod and Vyjuvek treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) and IV Efgartigimod treatment in Epidermolysis Bullosa Acquisita (EBA) improves wound healing and affects the levels of C7 antibody levels in serum. Fewer wounds, more rapidly...
What is the current status of trial NCT07011589?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2026-07. Estimated completion is 2028-01.
What interventions are being tested in trial NCT07011589?
The interventions under investigation include: Efgartigimod (BIOLOGICAL).
Who is sponsoring clinical trial NCT07011589?
This trial is sponsored by M. Peter Marinkovich, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07011589's enrollment target sits among peer trials
18 1720th of 2000 higher than 216 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia